BioWorld

May 26, 2005

Earlier-Stage Deals Demand 'Creative' Structuring Efforts

House Passes Stem Cell Bill; Bush Veto Looms On Horizon

Cylene Brings In $26M To Further Lead Cancer Drug

InterMune Finds Buyer For Amphotec In Three Rivers

Other News To Note

Encysive Submits Thelin NDA In PAH, Seeks Accelerated Review

Encysive Pharmaceuticals Inc. set its lead drug candidate, Thelin (sitaxsentan), on the pathway toward approval for pulmonary arterial hypertension by filing a new drug application with the FDA. (BioWorld Today) Read More

Today's news in brief

BioWorld

BioWorld briefs for Dec. 17, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for December 17, 2024.

Second insulin receptor offers new therapeutic avenues

BioWorld Science

Investigators at the Helmholtz Institute have shown that inceptor, an inhibitor of the insulin signaling pathway, acted by binding insulin and targeting it for...

Drug duo to Repare lack in gyno cancers? Phase I shows promise

BioWorld

Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

Mechanism underlying so-called idiopathic autism inception unveiled

BioWorld Science

Investigators at the Institute for Research in Biomedicine (IRB Barcelona) have unraveled how and why the absence of a neuronal microexon in cytoplasmic...